Cargando…

1210 A Phase 3, Randomized, Double-Blind, Non-inferiority Trial to Evaluate Efficacy and Safety of Isavuconazole versus Voriconazole in Patients with Invasive Mold Disease (SECURE): Outcomes in Neutropenic Patients

Detalles Bibliográficos
Autores principales:	Patterson, Thomas, Selleslag, Dominik, Mullane, Kathleen, Cornely, Oliver, Hope, William, Lortholary, Olivier, Zeiher, Bernhardt, Maher, Rochelle, Lee, Misun, Huang, Wenmei, Kontoyiannis, Dimitrios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2014
Materias:	IDWeek 2014 Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5782025/ http://dx.doi.org/10.1093/ofid/ofu051.98

Ejemplares similares

825 A Phase 3, Randomized, Double-Blind, Non-Inferiority Trial to Evaluate Efficacy and Safety of Isavuconazole vs Voriconazole in Patients with Invasive Mold Disease (IMD): Outcomes in Patients with Pulmonary Infections
por: Raad, Issam, et al.
Publicado: (2014)

1211 A Phase 3, Randomized, Double-Blind, Non-Inferiority Trial to Evaluate Efficacy and Safety of Isavuconazole versus Voriconazole in Patients with Invasive Mold Disease (SECURE): Outcomes in Invasive Aspergillosis Patients
por: Kontoyiannis, Dimitrios, et al.
Publicado: (2014)

824 An Open-Label Phase 3 Study of Isavuconazole (VITAL): Focus on Mucormycosis
por: Marty, Francisco M., et al.
Publicado: (2014)

466 Skin lesions in febrile neutropenic patients
por: Yemisen, Mucahit, et al.
Publicado: (2014)

204 Voriconazole Restriction in Addition to Therapeutic Drug Monitoring (TDM) Protocol Results in Optimized Dosing
por: Pettit, Natasha, et al.
Publicado: (2014)

434 Prevalence, Risk Factors, and Outcomes of Bacteremia Caused by Carbapenem-resistant Enterobacteriaceae in Neutropenic Patients with Hematologic Malignancies
por: Satlin, Michael J., et al.
Publicado: (2014)

1463 Immune Reconstitution Inflammatory Syndrome (IRIS) in Neutropenic Patients with Invasive Pulmonary Aspergillosis (IPA) during Neutrophil Recovery
por: Jung, Jiwon, et al.
Publicado: (2014)

1465 Pigmented Mold Endocarditis – Case Series and Review of the Literature
por: Hoz, Ricardo La, et al.
Publicado: (2014)

1466 Primary Cutaneous Mold Infections in Hematologic Malignancy with a Review of the Literature
por: Mai, Jane, et al.
Publicado: (2014)

468 RBX2660 (microbiota suspension) for Recurrent C. difficile Infection: 60-Day Interim Analysis of the PUNCH-CD Phase 2 Safety Study
por: Dubberke, Erik, et al.
Publicado: (2014)

457 Actinomyces Infection in Hematologic and Solid Cancer Patients at the University of Texas MD Anderson Cancer Center in 1998-2014
por: Gutierrez, Andres, et al.
Publicado: (2014)

Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response
por: Kovanda, Laura L., et al.
Publicado: (2017)

Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses
por: Thompson, George R., et al.
Publicado: (2016)

745 Risk of Peripheral Blood Eosinophilia and Hypersensitivity Reactions among Patients Receiving Outpatient Parenteral Antibiotics
por: Blumenthal, Kimberly, et al.
Publicado: (2014)

850. Real-world effectiveness and safety compared among isavuconazole, amphotericin B, and voriconazole in invasive mold disease patients
por: Qiu, Ye, et al.
Publicado: (2023)

Antibacterials/isavuconazole/voriconazole: Lack of efficacy: case report
Publicado: (2020)

313 Value of Discontinuation of Contact Precautions (CP) for Methicillin-Resistant Staphylococcus aureus (MRSA)
por: Shenoy, Erica S., et al.
Publicado: (2014)

409 Efficacy of Vancomycin against Biofilms of Neonatal Staphylococcus epidermidis Bloodstream Isolates
por: Simitsopoulou, Maria, et al.
Publicado: (2014)

Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial
por: Perfect, John R., et al.
Publicado: (2018)

Isavuconazole for COVID-19-Associated Invasive Mold Infections
por: Ullah, Nadir, et al.
Publicado: (2022)

Amphotericin-B-liposomal/isavuconazole/voriconazole: Lack of efficacy: 6 case report
Publicado: (2022)

Isavuconazole/piperacillin/tazobactam/voriconazole: Drug-induced liver injury: case report
Publicado: (2022)

Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials
por: Andes, David R., et al.
Publicado: (2018)

Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis
por: Harrington, Rachel, et al.
Publicado: (2016)

Breaking the mold: A case of pulmonary mucormycosis treated with isavuconazole
por: Huggins, Jonathan, et al.
Publicado: (2018)

304 Methicillin-resistant Staphylococcus aureus in Ohio EMS providers: A statewide cross-sectional study
por: Orellana, Robert, et al.
Publicado: (2014)

113 Procedure-specific Surgical Site Infection (SSI) Prevalence Widely Varies within Certain NHSN (National Healthcare Safety Network) Surgery Groups
por: Saeed, Mohammed, et al.
Publicado: (2014)

1124 Clinical characteristics of adult patients with influenza B and A infections during 2013/2014 flu season
por: Ahn, Mi Young, et al.
Publicado: (2014)

1543 Counting the Costs of Falsely Labeling Patients as HIV-Positive in Tahoua Region, Niger
por: Megill, Matthew
Publicado: (2014)

538 A Retrospective Study to Evaluate the Safety of Switching Antiretroviral Therapy (ART) to Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine (RPV/TDF/FTC) STR in Virologically Suppressed HIV-Infected Patients
por: Monczor, Ana, et al.
Publicado: (2014)

1067 Multi-Attribute Ranking Tool for Vaccines: Strategic Priority Setting to Support Vaccine Development
por: Madhavan, Guruprasad, et al.
Publicado: (2014)

1535 Knowledge, Practice, and Attitudes of University of California San Diego Medical Students with Regard to HIV and HIV Screening
por: Katsivas, Theodoros, et al.
Publicado: (2014)

1550 Can We Re-engage Patients with HIV Who Are Lost to Care? A Pilot Study in a Large Urban HIV Clinic
por: Lee, Dong Heun, et al.
Publicado: (2014)

473 Comparison of MicroScan System Prompt and Turbidity Methods for Measuring Vancomycin Minimum inhibitory concentration (MIC) against Methicillin-resistant Staphylococcus aureus (MRSA) with MIC of 2ug/ml, the Clinical Implications and economic impact of using alternative antimicrobial agents to vancomycin for MRSA with possible MIC of 2ug/ml
por: Kamran, Amir, et al.
Publicado: (2014)

870 The Epidemiology of CAUTI due to Candida spp. in the Intensive Care Unit (ICU) - Infection or Colonization?
por: Tashtoush, Nader, et al.
Publicado: (2014)

1454 Antifungal Susceptibility Patterns of a Global Collection of Fungal Isolates and Polysorbate-80 Effect on the Susceptibility of the Antifungal Classes
por: Castanheira, Mariana, et al.
Publicado: (2014)

766 Clinical Features and Outcome of Patients with Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) Infection
por: Alraddadi, Basem, et al.
Publicado: (2014)

1624 Risk Factors for Hospital-Acquired Clostridium difficile
por: Knepper, Bryan, et al.
Publicado: (2014)

1551 The Patient-Centered Medical Home: A Reality for HIV Care in Nigeria
por: Ahonkhai, Aimalohi, et al.
Publicado: (2014)

1663 Imported Exotic Infectious Diseases in Columbia, Missouri
por: Regunath, Hariharan, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_pdvbn4qoi803l10ukuoc3j3l8u